Chongqing Zhifei Biological Products Co Ltd
SZSE:300122

Watchlist Manager
Chongqing Zhifei Biological Products Co Ltd Logo
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Watchlist
Price: 28.22 CNY -5.21% Market Closed
Market Cap: 67.7B CNY
Have any thoughts about
Chongqing Zhifei Biological Products Co Ltd?
Write Note

Chongqing Zhifei Biological Products Co Ltd
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Chongqing Zhifei Biological Products Co Ltd
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Net Income (Common)
ÂĄ6B
CAGR 3-Years
-6%
CAGR 5-Years
26%
CAGR 10-Years
48%
Beigene Ltd
HKEX:6160
Net Income (Common)
-ÂĄ6.7B
CAGR 3-Years
16%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Net Income (Common)
ÂĄ2B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Net Income (Common)
ÂĄ1.2B
CAGR 3-Years
23%
CAGR 5-Years
34%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Net Income (Common)
ÂĄ1.8B
CAGR 3-Years
5%
CAGR 5-Years
N/A
CAGR 10-Years
23%
Imeik Technology Development Co Ltd
SZSE:300896
Net Income (Common)
ÂĄ1.9B
CAGR 3-Years
62%
CAGR 5-Years
72%
CAGR 10-Years
N/A
No Stocks Found

Chongqing Zhifei Biological Products Co Ltd
Glance View

Market Cap
67.6B CNY
Industry
Biotechnology

Chongqing Zhifei Biological Products Co., Ltd., founded in 1992, has swiftly ascended to become a key player in the Chinese biopharmaceutical landscape, primarily focusing on the development, manufacturing, and commercialization of vaccines and diagnostic products. The company operates with a vision to address pressing public health challenges, and it has established an impressive portfolio that includes vaccines for diseases like hepatitis, influenza, and COVID-19. With a robust research and development (R&D) foundation, Zhifei has secured multiple partnerships and collaborations, further bolstering its innovation pipeline and expanding its market reach. This strategic positioning within China's burgeoning biopharmaceutical sector highlights the company’s commitment to quality and safety, aligning closely with the growing national emphasis on health and disease prevention. For investors, Zhifei represents not just a stake in a successful vaccine manufacturer, but also an opportunity to participate in a transformative phase of public health management in China and beyond. The company’s recent advancements in vaccine technology and its ability to rapidly pivot in response to global health emergencies—exemplified by its expedited COVID-19 vaccine development—underscore its agility and competitive edge in a high-growth market. As the demand for advanced biological products continues to rise globally, Zhifei’s solid financial foundations, coupled with government support for the biopharmaceutical industry, position it as a compelling investment with the potential for substantial long-term returns. The confluence of innovation, strong governmental backing, and a commitment to improving public health makes Chongqing Zhifei a noteworthy candidate for investors looking to tap into the evolving healthcare landscape.

Intrinsic Value
46.22 CNY
Undervaluation 39%
Intrinsic Value
Price

See Also

What is Chongqing Zhifei Biological Products Co Ltd's Net Income (Common)?
Net Income (Common)
6B CNY

Based on the financial report for Jun 30, 2024, Chongqing Zhifei Biological Products Co Ltd's Net Income (Common) amounts to 6B CNY.

What is Chongqing Zhifei Biological Products Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
48%

Over the last year, the Net Income (Common) growth was -25%. The average annual Net Income (Common) growth rates for Chongqing Zhifei Biological Products Co Ltd have been -6% over the past three years , 26% over the past five years , and 48% over the past ten years .

Back to Top